1. Home
  2. SOLS vs PRAX Comparison

SOLS vs PRAX Comparison

Compare SOLS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SOLS

Solstice Advanced Materials Inc.

N/A

Current Price

$61.42

Market Cap

7.9B

Sector

Industrials

ML Signal

N/A

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$312.49

Market Cap

8.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOLS
PRAX
Founded
2025
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9B
8.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SOLS
PRAX
Price
$61.42
$312.49
Analyst Decision
Buy
Strong Buy
Analyst Count
3
13
Target Price
$55.00
$397.85
AVG Volume (30 Days)
4.1M
616.0K
Earning Date
02-11-2026
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.07
N/A
Revenue
$3,812,000,000.00
$7,463,000.00
Revenue This Year
$3.34
N/A
Revenue Next Year
$3.67
$14,827.76
P/E Ratio
$29.38
N/A
Revenue Growth
4.47
364.98
52 Week Low
$40.43
$26.70
52 Week High
$61.60
$326.91

Technical Indicators

Market Signals
Indicator
SOLS
PRAX
Relative Strength Index (RSI) N/A 66.64
Support Level N/A $266.93
Resistance Level N/A $306.16
Average True Range (ATR) 0.00 17.82
MACD 0.00 -1.32
Stochastic Oscillator 0.00 78.28

Price Performance

Historical Comparison
SOLS
PRAX

About SOLS Solstice Advanced Materials Inc.

Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Share on Social Networks: